A Novel Automated Chemiluminescence Method for Detecting Cerebrospinal Fluid Amyloid-Beta 1-42 and 1-40, Total Tau and Phosphorylated-Tau: Implications for Improving Diagnostic Performance in Alzheimer’s Disease DOI Creative Commons
Marina Arcaro, Chiara Fenoglio, María Serpente

et al.

Biomedicines, Journal Year: 2022, Volume and Issue: 10(10), P. 2667 - 2667

Published: Oct. 21, 2022

Recently, a fully automated instrument for the detection of Cerebrospinal Fluid (CSF) biomarker Alzheimer’s disease (AD) (low concentration Amyloid-beta 42 (Aβ42), high total tau (T-tau) and Phosphorylated-tau (P-tau181)), has been implemented, namely CLEIA. We conducted comparative analysis between ELISA CLEIA methods in order to evaluate analytical precision diagnostic performance novel system on 111 CSF samples. Results confirmed robust correlation methods, with an improvement accuracy new methodology single biomarkers their ratio values. For Aβ42 regression Passing−Bablok showed Pearson coefficient r = 0.867 (0.8120; 0.907% 95% CI p < 0.0001), T-tau analysis: 0.968 (0.954; 0.978% 0.0001) P-tau181: 0.946 (0.922; 0.962 5% 0.0001). The overall ROC AUC comparison more accurate automatic method: 0.94 (95% 0.89; 0.99 vs. 0.95 1.00 P-tau181 0.91 0.85; 0.98 0.95; method automation is comparable and, P-tau181, even better, as compared standard ELISA. Hopefully, future, could be useful clinical diagnosis also context studies.

Language: Английский

Implementation of an ultra-sensitive microwell-based electrochemical sensor for the detection of Alzheimer’s disease DOI
Soumi Roy, Sarang Kang, Kyu Yeong Choi

et al.

Biosensors and Bioelectronics, Journal Year: 2023, Volume and Issue: 247, P. 115898 - 115898

Published: Dec. 5, 2023

Language: Английский

Citations

11
Scope of Nanomaterials in Treating Neurological Disorders DOI Open Access

Aaryan Gupta,

Arpita Roy,

Kirtanjot Kaur

et al.

OBM Neurobiology, Journal Year: 2024, Volume and Issue: 08(01), P. 1 - 22

Published: Jan. 11, 2024

In the last decade, development in nanotechnology has been used intensively. By studying and nanomaterials, we can generate excellent responses healthcare related to neurological disorders. It also includes easy diagnosis of diseases their early stages, delivery genes, many more. Neurological disorders are one most sensitive topics. Therefore, nanomaterials promise treat as they highly efficient. Nanomaterials will significantly expand our knowledge how disease originates nervous system so that diagnose its stages. This review describe an overview paper present utilization with help recent data current research. focus on significant importance toxicology neurology. deal different applications studies impact developing new types treatment for Lastly, this discuss all challenges face promises future vast field.

Language: Английский

Citations

4
Exploratory Tau PET/CT with [11C]PBB3 in Patients with Suspected Alzheimer’s Disease and Frontotemporal Lobar Degeneration: A Pilot Study on Correlation with PET Imaging and Cerebrospinal Fluid Biomarkers DOI Creative Commons
Joachim Strobel, Elham Yousefzadeh-Nowshahr,

Katharina Deininger

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(7), P. 1460 - 1460

Published: July 1, 2024

Accurately diagnosing Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD) is challenging due to overlapping symptoms limitations of current imaging methods. This study investigates the use [11C]PBB3 PET/CT visualize tau pathology improve diagnostic accuracy. Given challenges with conventional imaging, PET/CT’s potential enhance accuracy was investigated by correlating cerebrospinal fluid (CSF) biomarkers, positron emission tomography (PET), computed (CT), amyloid-beta, Mini-Mental State Examination (MMSE). We conducted on 24 patients suspected AD or FTLD, alongside [11C]PiB (13 patients) [18F]FDG (15 patients). Visual quantitative assessments uptake using standardized value ratios (SUV-Rs) correlation analyses clinical were performed. The scans revealed distinct accumulation patterns; 13 had no faint (PBB3-negative) 11 moderate pronounced (PBB3-positive). Significant inverse correlations found between SUV-Rs MMSE scores, but not CSF-tau CSF-amyloid-beta levels. Here, we show that can reveal patterns correlate these cognitive impairment in neurodegenerative diseases. Our demonstrates [11C]PBB3-PET for visualizing assessing severity, offering a promising tool enhancing FTLD. Further research essential validate findings refine tau-specific PET practice, ultimately improving patient care treatment outcomes.

Language: Английский

Citations

4
Blood biomarker profiles in young-onset neurocognitive disorders: A cohort study DOI Creative Commons
Oneil G. Bhalala,

Jessica Beamish,

Dhamidhu Eratne

et al.

Australian & New Zealand Journal of Psychiatry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 17, 2025

Young-onset neurocognitive symptoms result from a heterogeneous group of neurological and psychiatric disorders which present diagnostic challenge. To identify such factors, we analysed the Biomarkers in Younger-Onset Neurocognitive Disorders cohort, study individuals <65 years old presenting with for diagnosis who have undergone cognitive biomarker analyses. Sixty-five participants (median age at assessment 56 years, 45% female) were recruited during their index presentation to Royal Melbourne Hospital Neuropsychiatry Centre, tertiary specialist service Melbourne, Australia, categorized as either early-onset Alzheimer's disease (n = 18), non-Alzheimer's neurodegeneration 23) or primary 24). Levels neurofilament light chain, glial fibrillary acidic protein phosphorylated-tau 181, apolipoprotein E genotype late-onset polygenic risk scores determined. Information-theoretic model selection identified discriminatory factors. Neurofilament 181 levels elevated compared other categories. A multi-omic that combination blood biomarkers, but not score, discriminated between (area under curve ⩾ 0.975, 95% confidence interval: 0.825-1.000). Phosphorylated-tau alone significantly causes 0.950, 0.877-1.00). Discriminating disease, young-onset is possible by combining profiles biomarkers. These results support utilizing biomarkers work-up highlight need development disease-specific score.

Language: Английский

Citations

0
Developing Non-Invasive Molecular Markers for Early Risk Assessment of Alzheimer's Disease DOI Creative Commons

Tapas Kumar Sur,

Tanmoy Mondal, Zarish Noreen

et al.

Biomarkers in Neuropsychiatry, Journal Year: 2025, Volume and Issue: unknown, P. 100120 - 100120

Published: Jan. 1, 2025

Language: Английский

Citations

0
Distinctive associations between plasma p-tau181 levels and hippocampal subfield volume across the Alzheimer's disease continuum DOI Creative Commons

A Rich,

Hwamee Oh

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 28, 2025

Abstract Background Plasma p-tau181 is a promising diagnostic marker of Alzheimer’s disease (AD) pathology, reflecting amyloid accumulation, tau deposition, and downstream neurodegeneration that leads to cognitive impairment. However, the specificity plasma AD-related pathology remains unclear. Objective To assess whether differentially associated with volumetric changes in distinct hippocampal subfields they mediate relationship between cognition across AD continuum. Methods 213 participants normal (N=57), mild impairment (N=109), (N=47) from Disease Neuroimaging Initiative (ADNI) were included for cross-sectional analyses subfield volume was quantified using Automatic Segmentation Hippocampal Subfields (ASHS) software. A subset (n=89) evaluated one-year longitudinal volume. Results Higher levels (pg/mL) decreased volumes CA1 dentate gyrus, bilaterally, right entorhinal cortex ( ps < 0.05). Additionally, these partially mediated ADNI memory executive function composite scores. Baseline p-tau181, however, did not predict atrophy groups. Conclusions are closely related both age- neurodegeneration. Elevated may reflect DG detrimental effect on cognition.

Language: Английский

Citations

0
Integrating NLP and LLMs to discover biomarkers and mechanisms in Alzheimer's disease DOI Creative Commons
Jin‐Won Song, Junjie Huang, Richen Liu

et al.

SLAS TECHNOLOGY, Journal Year: 2025, Volume and Issue: unknown, P. 100257 - 100257

Published: Feb. 1, 2025

Alzheimer's disease (AD) is a progressive neurological condition characterized by cognitive decline, memory loss, and aberrant behaviour. It affects millions of people globally one the main causes dementia. The neurodegenerative known as AD has intricate, multifaceted mechanisms that make it difficult to comprehend identify in its early stages. Conventional diagnostic techniques frequently fail detect By combining Natural Language Processing (NLP) Large Models (LLMs), this research suggests novel approach for identifying potential biomarkers underlying AD. Clinical data gathered from publicly accessible databases healthcare facilities, including genetic information, neuroimaging scans, medical records. pre-processing unstructured clinical notes involves tokenization profiles are normalized Z-score normalization consistency. Multi-Input Convolutional Neural Networks (MI-CNN) employed efficiently fuse diverse sources, allowing thorough analysis. Key linked identified categorized using Genetic Algorithm combined with Bidirectional Encoder Representations Transformers (BERT) (GenBERT). fine-tuning BERT's hyperparameters optimization approaches, GenBERT enables effective analysis large datasets, such patient histories, data, notes. combination strategy increases feature selection model's capacity minute genomic linguistic patterns suggestive goal integrated provide tools new insights into pathogenesis disease, which could transform methods detecting treating As concerns prediction, model performs better than current techniques, obtaining highest accuracy (98.30%) F1-score (0.97), well greater precision (0.95) recall (0.92). Additionally, demonstrates reliably both positive negative cases sensitivity (98.65%) specificity (99.73%). Overall, offers trustworthy useful tool diagnosis.

Language: Английский

Citations

0
Blood-Based β-Amyloid and Phosphorylated Tau (p-Tau) Biomarkers in Alzheimer’s Disease: A Systematic Review of Their Diagnostic Potential DOI Open Access

Meghana Dasari,

Joel Abraham Kurian,

Sumanth Gundraju

et al.

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and neuropathological features such as amyloid-β (Aβ) plaques phosphorylated tau (p-Tau) tangles. Blood-based biomarkers of Aβ p-Tau have emerged promising tools for early diagnosis, monitoring, risk stratification AD. This systematic review evaluates current evidence on the diagnostic utility blood in followed Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA) guidelines. A comprehensive literature search was conducted across PubMed, Scopus, Web Science studies published between 2011 2024. synthesizes findings from 33 peer-reviewed to evaluate prognostic these biomarkers. Results demonstrate that levels strongly correlate with cerebrospinal fluid (CSF) neuroimaging measures AD pathology. Among analyzed, (including p-Tau181 p-Tau217) consistently exhibited superior accuracy, particularly distinguishing mild impairment (MCI) cognitively normal individuals. The combination further improved precision, supporting their complementary roles pathology detection. Despite findings, significant heterogeneity among underscores need assay standardization, validation diverse populations, longitudinal research establish clinical utility. study concludes blood-based represent advance diagnostics, offering non-invasive, cost-effective, scalable solutions detection therapeutic monitoring.

Language: Английский

Citations

0
Success of anti-amyloid therapy answers few but raises many questions DOI
Atanu Biswas

Annals of Medical Science and Research, Journal Year: 2025, Volume and Issue: 4(1), P. 1 - 3

Published: Jan. 1, 2025

Language: Английский

Citations

0
Increase in Mitochondrial D-Loop Region Methylation Levels in Mild Cognitive Impairment Individuals DOI Open Access
Andrea Stoccoro, Filippo Baldacci, Roberto Ceravolo

et al.

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(10), P. 5393 - 5393

Published: May 12, 2022

Methylation levels of the mitochondrial displacement loop (D-loop) region have been reported to be altered in brain and blood Alzheimer's disease (AD) patients. Moreover, a dynamic D-loop methylation pattern was observed transgenic AD mice along with progression. However, investigations on cells patients prodromal phases not performed so far. The aim this study analyze by means MS-HRM technique peripheral 14 mild cognitive impairment (MCI) patients, 18 early stage 70 advanced 105 healthy control subjects. We found higher MCI than subjects were stages disease, but those at stages. present pilot shows that differ different pathology, suggesting further studies deserve order validate usefulness analysis as biomarker for detection AD.

Language: Английский

Citations

16